Last updated: October 15, 2026
Celgene is no longer an independent company. Bristol Myers Squibb completed its acquisition of Celgene on Nov. 20, 2019, creating a combined oncology, hematology and immunology business. Celgene’s assets remain commercially important, led by Revlimid, Pomalyst, Abraxane, Breyanzi and Abecma. The primary strategic issue is the transition from mature multiple-myeloma revenue to newer cell therapies and next-generation oncology products while managing generic erosion of lenalidomide and pomalidomide.
BMS paid approximately $74 billion in stock and assumed debt for Celgene. The deal added a large commercial base, late-stage oncology programs and cell-therapy capabilities, but also concentrated BMS exposure in products with complex patent and exclusivity profiles (Bristol Myers Squibb, 2019).
What was Celgene’s market position before Bristol Myers Squibb acquired it?
Celgene was a specialty biopharmaceutical company concentrated in hematology, oncology and inflammatory diseases. Its commercial position was built on oral immunomodulatory drugs and specialty formulations.
| Product |
Active ingredient or platform |
Main indications |
Celgene-era strategic role |
| Revlimid |
Lenalidomide |
Multiple myeloma, myelodysplastic syndromes, mantle-cell lymphoma |
Primary revenue engine |
| Pomalyst/Imnovid |
Pomalidomide |
Relapsed or refractory multiple myeloma |
Later-line myeloma franchise |
| Abraxane |
Albumin-bound paclitaxel |
Breast, pancreatic and non-small-cell lung cancer |
Specialty oncology formulation |
| Otezla |
Apremilast |
Psoriasis and psoriatic arthritis |
Immunology growth asset; sold to Amgen in 2019 |
| Inrebic |
Fedratinib |
Myelofibrosis |
Hematology growth asset |
| Breyanzi |
Lisocabtagene maraleucel |
B-cell malignancies |
CD19-directed CAR-T platform |
| Abecma |
Idecabtagene vicleucel |
Multiple myeloma |
BCMA-directed CAR-T platform, commercialized with 2seventy bio |
Celgene reported 2018 revenue of approximately $15.3 billion. Revlimid generated about $9.7 billion, making up roughly 63% of total company revenue. Pomalyst generated approximately $2.8 billion and Abraxane about $1.1 billion (Celgene Corporation, 2019).
The acquisition therefore gave BMS a powerful near-term revenue base but also created a concentrated patent-cliff risk.
How much revenue exposure does BMS have to former Celgene products?
The former Celgene portfolio remains material to BMS, although Revlimid revenue has declined as authorized and generic competition expanded.
| Product |
Approximate 2023 BMS revenue contribution |
Revenue condition |
| Revlimid |
About $6 billion |
Erosion from U.S. generic and authorized-generic competition |
| Pomalyst/Imnovid |
Approximately $3 billion |
Later-line demand remains strong; patent protection is longer |
| Abraxane |
Approximately $1 billion |
Mature oncology product with generic and competitive pressure |
| Breyanzi |
Less than $1 billion |
Growth depends on label expansion and manufacturing capacity |
| Abecma |
Several hundred million dollars |
Competing BCMA therapies and treatment-line movement pressure growth |
BMS reported total 2023 revenue of approximately $45 billion. Revlimid, Pomalyst and Abraxane together represented a substantial portion of the company’s legacy oncology base, even though the products were no longer at peak growth (Bristol Myers Squibb, 2024).
The key commercial shift is from high-margin oral drugs with established distribution to cell therapies requiring patient identification, leukapheresis, manufacturing slots, bridging therapy and specialized treatment centers.
What patents protect Revlimid and when does lenalidomide lose exclusivity?
Revlimid is protected by a layered estate covering lenalidomide composition, polymorphs, formulations, dosing regimens and methods of treatment. The relevant protection is not a single patent-expiration date.
| Patent or protection category |
Representative protection |
Strategic effect |
| Original lenalidomide composition |
U.S. Patent No. 5,635,517 |
Expired after pediatric-extension treatment |
| Solid-state and polymorph protection |
U.S. Patent No. 7,465,800 and related families |
Extended protection beyond the original compound patent |
| Multiple-myeloma treatment methods |
Method-of-use patents and continuation families |
Limited generic labeling and launch scope |
| Risk-management distribution system |
REMS and controlled-distribution requirements |
Operational barrier, not patent exclusivity |
| Regulatory exclusivity |
Orphan and supplemental approvals |
Supports indication-specific commercial protection |
Lenalidomide entered the U.S. generic market through settlement-based launches rather than an immediate unrestricted launch. Several generic companies received limited launch rights, while broader competition was deferred. The settlement framework allowed certain generic quantities before the principal agreed entry date and created a staged erosion profile.
The practical U.S. risk is therefore a multi-year decline rather than a single-day loss of exclusivity. Generic applicants can launch under carve-outs for protected indications while avoiding patented methods of use. This structure reduces the initial addressable generic market but does not eliminate long-term erosion.
The FDA Orange Book lists relevant Revlimid patents and regulatory exclusivity information. BMS also reported patent litigation and settlements involving multiple abbreviated new drug application applicants (U.S. Food and Drug Administration, 2024a; Bristol Myers Squibb, 2024).
What patents protect Pomalyst and when does pomalidomide lose exclusivity?
Pomalyst is protected by composition, formulation and method-of-use patents covering pomalidomide and its use in multiple myeloma. Its exclusivity profile is more favorable than Revlimid’s because the product entered the market later and relies on later patent families.
| Product |
Key U.S. protection profile |
Generic risk |
| Pomalyst |
Composition and method patents extending into the late 2020s or around 2030, subject to patent-specific adjustments |
Lower near-term risk than Revlimid |
| Pomalyst dosing regimens |
Treatment-method claims for relapsed or refractory disease |
Carve-out litigation risk |
| REMS distribution |
Restricted distribution through certified pharmacies and prescribers |
Operational friction, not a substitute for patent protection |
Representative Pomalyst patent families include U.S. Patent Nos. 6,696,085, 7,189,740 and 8,198,262, although the Orange Book listing and terminal-disclaimer status must be reviewed patent by patent. Patent-term adjustments, pediatric extensions, terminal disclaimers and settlement agreements affect the effective entry date.
Pomalyst is strategically important because it extends BMS’s immunomodulatory franchise after Revlimid erosion. Its main weakness is therapeutic substitution. Physicians may move patients toward proteasome inhibitors, anti-CD38 antibodies, bispecific antibodies and BCMA-directed therapies rather than use a later-line immunomodulatory drug.
What formulation patents protect Abraxane?
Abraxane is an albumin-bound nanoparticle formulation of paclitaxel. Its commercial differentiation came from solvent-free delivery, eliminating the need for Cremophor-based solvent systems used in conventional paclitaxel formulations.
Patent protection has covered:
- Albumin-bound paclitaxel nanoparticles.
- Particle-size and composition parameters.
- Manufacturing and formulation processes.
- Administration methods and oncology uses.
Representative Abraxane-related U.S. patent families include U.S. Patent Nos. 5,399,363 and 7,820,788, among other continuation and formulation families. The earliest core protection has expired, while later patents have provided narrower protection for formulation and manufacturing features.
Abraxane faces competition from conventional paclitaxel, docetaxel, nanoparticle formulations and other oncology regimens. Its competitive position depends less on broad compound exclusivity and more on clinical convenience, treatment protocols, contracting and physician familiarity.
What is the Orange Book status of former Celgene products?
Small-molecule products such as Revlimid, Pomalyst and Abraxane are subject to Orange Book listing. Biologic cell therapies are not generally protected through the Orange Book in the same manner.
| Product |
FDA regulatory category |
Orange Book treatment |
Primary exclusivity issue |
| Revlimid |
Small molecule |
Listed patents and regulatory exclusivity |
Paragraph IV challenges and staged generic entry |
| Pomalyst |
Small molecule |
Listed patents |
Later patent expiration and method-of-use disputes |
| Abraxane |
Drug product with complex formulation |
Listed patents may cover formulation and use |
Complex generic development |
| Breyanzi |
Biologic cell therapy |
Not an Orange Book small-molecule listing |
Biologics Price Competition and Innovation Act pathway |
| Abecma |
Biologic cell therapy |
Not an Orange Book small-molecule listing |
Biosimilar and manufacturing complexity |
The FDA’s Purple Book is the more relevant reference for biologic exclusivity and biosimilar interchangeability information. Cell therapies also face manufacturing, comparability and clinical-performance barriers that are not captured by an Orange Book patent listing (U.S. Food and Drug Administration, 2024b).
Which companies are challenging Celgene and BMS products?
Generic competition is strongest against Revlimid and Abraxane. Major generic companies that have pursued lenalidomide or related market opportunities include Teva, Natco, Dr. Reddy’s Laboratories, Cipla and other ANDA sponsors. Entry rights have often been controlled by litigation settlements.
The competitive challenge to Pomalyst is more limited because of later patent protection and the complexity of designing a commercially viable generic program around a highly regulated oncology product.
Cell-therapy competition is more direct and clinically disruptive:
| BMS/Celgene product |
Principal competitors |
| Breyanzi |
Yescarta, Tecartus, Kymriah, newer CD19 CAR-T products |
| Abecma |
Carvykti and emerging BCMA CAR-T and bispecific products |
| Revlimid and Pomalyst |
Darzalex, Kyprolis, Velcade, Empliciti, bispecific antibodies and BCMA therapies |
| Abraxane |
Conventional paclitaxel, docetaxel and competing nanoparticle or albumin-based formulations |
The multiple-myeloma market is shifting toward earlier use of anti-CD38 antibodies, BCMA-directed therapies and bispecific antibodies. This threatens the duration of use for immunomodulatory drugs even before complete generic erosion.
What FDA regulatory milestones define the former Celgene portfolio?
| Date |
Milestone |
| 2005 |
FDA approved Revlimid for transfusion-dependent anemia associated with myelodysplastic syndromes |
| 2005 |
FDA approved Abraxane for metastatic breast cancer |
| 2013 |
FDA approved Pomalyst for relapsed and refractory multiple myeloma |
| 2015 |
FDA approved Abraxane for metastatic pancreatic adenocarcinoma |
| 2019 |
BMS completed acquisition of Celgene |
| 2021 |
FDA approved Abecma, the first BCMA-directed CAR-T therapy |
| 2021 |
FDA approved Breyanzi for relapsed or refractory large B-cell lymphoma |
| 2023-2024 |
FDA expanded Breyanzi’s use in additional B-cell malignancy settings |
| 2024 |
FDA expanded Breyanzi into earlier-line large B-cell lymphoma treatment |
Breyanzi’s label expansion is strategically important because earlier treatment lines offer a larger eligible population than heavily pretreated disease. It also increases manufacturing and treatment-center requirements.
How strong is the Celgene-BMS patent estate?
The estate is strongest where several forms of protection overlap:
- Later-generation products have composition and method-of-use patents.
- Complex formulations create manufacturing barriers.
- Cell therapies depend on proprietary constructs, cell-processing methods and manufacturing know-how.
- Regulatory controls limit rapid generic substitution.
- Settlement agreements can delay or stage competitive entry.
The estate is weaker for mature products where the original composition patent has expired and remaining claims are narrow. Revlimid is commercially protected through a managed transition rather than an absolute barrier. Abraxane has a weaker exclusivity profile because conventional paclitaxel and other oncology formulations provide therapeutic alternatives.
For Breyanzi and Abecma, the primary barriers are not only patents. They include:
- Viral-vector and cell-processing know-how.
- Manufacturing capacity.
- Chain-of-identity controls.
- Release testing.
- Clinical comparability.
- Treatment-center accreditation.
- Physician and payer contracting.
- Patient referral infrastructure.
These barriers can delay competition even when patent claims are challenged, but they do not eliminate long-term biosimilar or follow-on cell-therapy risk.
What patent litigation and Paragraph IV risks affect BMS?
The highest Paragraph IV exposure has historically involved Revlimid. ANDA applicants have challenged listed patents covering lenalidomide composition, polymorphs, formulations and treatment methods. BMS and Celgene used litigation and settlement agreements to control the timing, quantity and scope of generic entry.
The main legal issues include:
- Whether listed patents properly cover the proposed generic product.
- Whether method-of-use claims can be avoided through labeling carve-outs.
- Whether polymorph or formulation claims are valid and infringed.
- Whether terminal disclaimers limit patent-term duration.
- Whether settlement terms comply with antitrust requirements.
- Whether authorized-generic supply changes the commercial impact of third-party entry.
Pomalyst has similar legal risk but a later expected erosion profile. Abraxane litigation is more formulation- and manufacturing-focused. Breyanzi and Abecma litigation is expected to involve biologic patent claims, cell constructs, vectors, manufacturing processes and treatment methods rather than traditional ANDA litigation.
How does BMS compare with competing oncology manufacturers?
| Company |
Competitive strength |
Exposure relative to BMS |
| Johnson & Johnson |
Darzalex, Carvykti and broad hematology infrastructure |
Strong in multiple myeloma and antibody-based therapy |
| AbbVie |
Imbruvica, Venclexta and hematology partnerships |
Strong in targeted hematologic oncology |
| Gilead/Kite |
Yescarta and Tecartus |
Leading CAR-T manufacturing and commercial infrastructure |
| Novartis |
Kymriah and radioligand capabilities |
Cell therapy and precision oncology diversification |
| Roche |
Hematology antibodies and diagnostics |
Broad biologics and diagnostic integration |
| Amgen |
Bispecific antibodies and oncology biologics |
Strong threat to older myeloma regimens |
| 2seventy bio |
Abecma partnership with BMS |
Specialized BCMA cell-therapy exposure |
BMS has an unusually broad position across oral immunomodulators, antibodies, CAR-T therapies and immune-oncology products. Its weakness is the speed of transition. Mature Celgene products generate substantial cash but face erosion, while cell therapies require higher execution intensity and have more variable demand.
What generic launch scenarios exist for Revlimid, Pomalyst and Abraxane?
Revlimid
The most likely commercial pattern is staged generic entry:
- Limited authorized or settlement-based volumes.
- Initial competition in non-protected indications.
- Progressive expansion as additional patent barriers fall.
- Declining net price and market share for BMS.
- Continued residual demand from treatment protocols and physician familiarity.
Pomalyst
The likely scenario is a later and more concentrated launch after key composition and method patents expire or are invalidated. Because Pomalyst is used in later-line disease, generic substitution may be moderated by treatment changes toward BCMA therapies and bispecific antibodies.
Abraxane
Abraxane faces both generic and therapeutic competition. A successful complex generic must demonstrate equivalence for a nanoparticle formulation, not merely reproduce paclitaxel’s active ingredient. Manufacturing economics and clinical substitution will determine the pace of erosion.
What licensing deals support the former Celgene competitive position?
BMS inherited several important partnerships:
- Abecma is commercialized through a partnership between BMS and 2seventy bio.
- Celgene licensed and collaborated on multiple oncology and hematology programs before the BMS acquisition.
- BMS retained rights and development capabilities associated with Celgene’s cell-therapy portfolio.
- Celgene’s Otezla business was divested to Amgen as part of the regulatory process for the BMS transaction.
Partnership economics matter because royalties, co-development obligations and regional rights reduce the amount of product revenue retained by BMS. They also distribute manufacturing and clinical-development risk.
What geographic coverage does the Celgene-BMS portfolio have?
Revlimid, Pomalyst and Abraxane have broad global commercial coverage, but patent terms and generic-entry dates vary by country. The United States remains the most important profit market because of higher oncology pricing and the commercial significance of ANDA litigation.
Europe typically experiences earlier multi-source competition after patent expiry or settlement-based entry. Japan and other regulated markets apply separate patent-term extensions, pricing reviews and reimbursement controls. Cell-therapy availability is narrower because treatment depends on certified centers, manufacturing logistics and national reimbursement decisions.
Geographic risk should be assessed product by product. A U.S. patent settlement does not establish the effective entry date in Europe, Japan, Canada or emerging markets.
What strategic priorities should BMS pursue after Celgene?
BMS’s strategic priorities are clear:
- Replace Revlimid cash flow with growth from Breyanzi, Abecma, Opdivo combinations and newer hematology products.
- Extend cell-therapy labels into earlier treatment lines where clinical demand is larger.
- Improve manufacturing turnaround times and treatment-center throughput.
- Defend Pomalyst and other mature assets through lifecycle management.
- Use authorized-generic and contracting strategies to manage Revlimid erosion.
- Expand beyond multiple myeloma as bispecific antibodies and CAR-T therapies compete for the same patients.
- Protect manufacturing know-how, process patents and cell-engineering capabilities.
- Maintain a balanced deal strategy that does not recreate excessive dependence on one product franchise.
The central investment question is whether newer products can replace the high-margin economics of Revlimid before generic erosion materially reduces the inherited Celgene revenue base.
Key Takeaways
- Celgene is a former independent company whose assets are now integrated into Bristol Myers Squibb.
- Revlimid remains the largest inherited asset but has entered a managed generic-erosion phase.
- Pomalyst has a longer protection profile but faces therapeutic substitution from BCMA therapies and bispecific antibodies.
- Abraxane has formulation and manufacturing differentiation but limited broad compound exclusivity.
- Breyanzi and Abecma provide strategic growth but require complex manufacturing and treatment-center infrastructure.
- The former Celgene estate is strongest where patents are combined with biologic manufacturing, regulatory and distribution barriers.
- BMS’s primary competitive challenge is replacing mature oral oncology revenue with cell therapy and next-generation hematology growth.
FAQs About Celgene and Bristol Myers Squibb’s Competitive Position
Is Celgene still a separate pharmaceutical company?
No. Bristol Myers Squibb completed the acquisition of Celgene on Nov. 20, 2019. Celgene products are now reported within BMS business segments.
Does Revlimid still have patent protection in the United States?
Yes. Revlimid has had multiple patent and settlement protections, but generic and authorized-generic entry has already occurred under staged arrangements. The commercial impact increases as additional restrictions expire.
Are Breyanzi and Abecma listed in the Orange Book?
No. They are biologic cell therapies. Their exclusivity and follow-on competition are evaluated under biologic regulatory frameworks, including the Purple Book and the BPCI Act.
Which product creates the greatest near-term patent risk for BMS?
Revlimid creates the greatest direct generic risk because of its size and the existence of multiple ANDA applicants. Pomalyst creates a later risk, while Breyanzi and Abecma face biologic, manufacturing and clinical competition rather than conventional small-molecule generic entry.
Can a biosimilar replace a CAR-T therapy automatically?
No. A follow-on cell therapy would face manufacturing, clinical, regulatory and treatment-center requirements beyond ordinary biosimilar substitution. Automatic interchangeability is not equivalent to generic substitution for an oral drug.
References
- Bristol Myers Squibb. (2019). Bristol-Myers Squibb completes acquisition of Celgene. https://news.bms.com
- Bristol Myers Squibb. (2024). 2023 annual report. https://www.bms.com/investors
- Celgene Corporation. (2019). 2018 annual report. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Food and Drug Administration. (2024a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
